Adamas Pharma Revenue, Profits - ADMS Quarterly Income Statement

Add to My Stocks
$27.1 $0.65 (2.46%) ADMS stock closing price Mar 16, 2018 (Closing)

Financial analysis of Adamas Pharma involves more than just checking the Adamas Pharma stock price, by looking at the financial statements of the company in detail. An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $- for 2017 Q3 impacts the ADMS stock. Investors typically check year over year or quarter over quarter revenue growth. One also needs to look at Adamas Pharma assets, operating expenses and Adamas Pharma free cash flow. The Adamas Pharma profit and loss statement shows revenue of $- for 2017 Q3. Revenue has decreased by 0 QoQ for ADMS stock.

View and download details of revenue and profits for Adamas Pharma for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q3
Adamas Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)---------
Adamas Pharma Gross Profit
Research & Development Expense6.45M7.17M7.08M7.06M7.43M9.22M7.52M9.7M9.96M
Selling General & Admin Expense16.06M13.11M9.14M8.29M7.34M8.05M6.64M6.9M5.8M
Income Before Depreciation Depletion Amortization-22.52M-20.28M-16.23M-15.3M-14.64M-17.06M-13.98M-16.07M-14.99M
Depreciation Depletion Amortization---------
Non Operating Income---------
Interest Expense1.67M--------
Adamas Pharma Pretax Income
Provision for Income Taxes--0.05M--0.11M----5.27M-0.05M
Investment Gains Losses---------
Other Income---------
Income Before Extraordinaries & Disc Operations-23.36M-20.75M-16.03M-14.96M-14.39M-16.88M-13.83M-10.69M-14.86M
Extraordinary Items & Discontinued Operations---------
Adamas Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS22.57M22.39M22.21M21.99M21.94M21.65M21.25M18.44M18.4M
Average Shares used to compute Basic EPS22.57M22.39M22.21M21.99M21.94M21.65M21.25M18.44M18.4M
Income Before Nonrecurring Items-23.36M-20.75M-16.03M-14.96M-14.39M-16.88M-13.83M-10.69M-14.86M
Income from Nonrecurring Items---------
Adamas Pharma Earnings Per Share Basic Net
Adamas Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-1.04-0.93-0.72-0.68-0.66-0.78-0.65-0.58-0.81
Preferred Dividends Acc Pd---------
Dividends Common0.00--------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Adamas Pharma stock analysis involves checking at least a few of the important things like:

  • Topline: A growing topline, as seen from the Adamas Pharma revenue chart, as isn't the case with Adamas Pharma indicates a sagging business. One needs to compare the QoQ topline or sales growth of ADMS stock with its peers like CBAY stock and VYGR stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: Most businesses like Adamas Pharma try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called statement of revenue and expense. The ADMS financials along with Adamas Pharma historical stock prices provide a lot of details about the firm.

Adamas Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield